Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22623745 | 0.90 | MMP2 (0.42) | CRBNDDB1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL22623660 | 0.77 | MAPT (0.45) | CRBNDDB1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3631245 | 0.73 | MAPT (0.47) | CRBNDDB1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL25908091 | 0.71 | DDB1 (0.51) | CRBNDDB1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5691931 | 0.69 | DDB1 (0.49) | CRBNDDB1ALDH1A1CA2 | |
| SCHEMBL22623720 | 0.66 | CRBN (0.43) | CRBNDDB1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL8300066 | 0.65 | DDB1 (0.67) | CRBNDDB1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1567424 | 0.65 | DDB1 (0.67) | CRBNDDB1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11663631 | 0.65 | DDB1 (0.43) | CRBNDDB1MAPTCA2 | |
| SCHEMBL22623670 | 0.65 | CRBN (0.41) | CRBNDDB1MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | CRBN 1/4885DDB1 304/4885MAPT 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.